Pharmaust Limited (ASX:PAA)


right-arrow Created with Sketch. 0 (0%)
MCAP $30.10M
Last trade 10.39am 28/01/2022 20mins delayed

Latest Announcements

15/12/2021 Price SensitivePSPAAPharmaust Limited
13/12/2021 Price SensitivePSPAAPharmaust Limited
01/12/2021 Price SensitivePSPAAPharmaust Limited
17/11/2021 Price SensitivePSPAAPharmaust Limited
16/11/2021PAAPharmaust Limited
16/11/2021PAAPharmaust Limited
15/11/2021 Price SensitivePSPAAPharmaust Limited
12/11/2021PAAPharmaust Limited

Company Overview

Pharmaust Limited is an Australia-based clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The Company's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. It has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The Company has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.

PAA in the news

PharmAust’s (PAA) wholly owned subsidiary Epichem is awarded an extension to its…
PharmAust’s (PAA) upcoming human trials receives a major boost as the company’s…
PharmAust (PAA) sets a start date for its clinical trials for its…
PharmAust (PAA) signs agreements to expand its canine lymphoma studies into New…

Search Previous Announcements